Pluripotent embryonic stem cell is the critical ingredient for making complicated genetically engineered animals, which can be used for the production of many valuable biologics. ATGC was awarded this grant to utilize the most up-to-date knowledge on the ground state of pluripotency, to derive germline competent embryonic stem cells from the rabbit blastocyst. Success of the project will enable us to produce sophisticated genetically engineered rabbits that can be used for the production of therapeutic biologics such like human antibodies. For details of the technology please search Project Number 1R41OD023245 in NIH RePORTER.

Homologous recombination is the major biological mechanism underlying the gene correction and genetic modification using programmable nucleases such as CRISPR/Cas9. Currently the efficiency of homologous recombination remains low and is a bottleneck problem for gene editing. ATGC was awarded this grant to develop a RAD51 augmentation method to improve the CRISPR/Cas9 mediated homologous recombination rate. For details of the technology please search Project Number 1R41GM122181 in NIH RePORTER.

Programmable nuclease technologies, especially CRISPR/Cas9 have revolutionized the field of gene editing, and have been credited with the potential to cure genetic defects. ATGC was awarded this grant to formulate and test new hyperbranched polymers for the effective packaging and delivery of Cas9 plasmid DNA, to enable its therapeutic application in vitro and in vivo. For details of the technology please search Project Number 1R42TR001711 in NIH RePORTER.